-
$1 billion in value cuts, 10 product launches deliberate
Moderna headquarters, exterior view, Cambridge, Massachusetts, USA. Plexi Images | GHI | UCG | Universal Images Group | Getty Images Moderna on Thursday said it plans to cut around $1.1 billion in expenses by 2027 and win approvals for several new products as it charts a path forward after the rapid decline of its Covid business. …
-
Eli Lilly might develop into the primary $1 trillion healthcare inventory
A sign with the company logo outside the headquarters of Eli Lilly and Company in Indianapolis, Indiana, March 17, 2024. Scott Olson | Getty Images A version of this article first appeared in CNBC’s Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions. Earlier this…
-
We’re taking an almost 300% revenue on a scorching drug inventory
Shortly after the opening bell, we’ll be selling 10 shares of Eli Lilly at roughly $958 each. Following Monday’s trade, Jim Cramer’s Charitable Trust will own 100 shares of LLY, decreasing its weighting to 2.85% from about 3.13%. Now that we are no longer restricted, we are selling some Eli Lilly shares. We downgraded Lilly…
-
Eli Lilly releases new, cheaper type of weight reduction drug
Eli Lilly on Tuesday released a new form of its weight loss drug Zepbound for roughly half its usual monthly list price to reach millions of patients without insurance coverage for the popular injection, such as those with Medicare. The move also aims to expand the supply of Zepbound in the U.S. as demand skyrockets,…
-
U.S. will provide free at-home kits beginning late September
Images By Tang Ming Tung | DigitalVision | Getty Images The Biden administration on Friday said it will resume offering free at-home Covid-19 tests to American households in late September as the virus has gained a stronger foothold in the U.S. this summer. Americans will soon be able to use COVIDtests.gov to request four free…
-
Eli Lilly weight reduction drug cuts threat of creating diabetes in trial
Eli Lilly’s highly popular weight loss drug reduced the risk of developing Type 2 diabetes by 94% in obese or overweight adults with prediabetes compared with a placebo, according to initial results from a long-term study released Tuesday. The late-stage trial on tirzepatide, the active ingredient in the company’s weight loss injection Zepbound and diabetes…
-
Mpox vaccine maker Bavarian Nordic seeks ‘essential’ approval for teenagers
Jackyenjoyphotography | Moment | Getty Images LONDON — Danish biotech company Bavarian Nordic said Friday that it had submitted data to the European Union’s drug regulator to extend the use of its mpox vaccine for teenagers. CEO Paul Chaplin told CNBC that the expanded approval for 12 to 17 year-olds would be crucial in tackling…
-
Eli Lilly (LLY) earnings Q2 2024
Eli Lilly on Thursday reported second-quarter earnings and revenue that blew past expectations and hiked its full-year revenue outlook by $3 billion as sales of its blockbuster diabetes drug Mounjaro and weight loss injection Zepbound spike. Shares of Eli Lilly closed more than 9% higher on Thursday. The drugmaker now expects revenue for the year…
-
CVS Well being (CVS) earnings Q2 2024
The CVS pharmacy logo is displayed on a sign above a CVS Health Corp. store in Las Vegas, Nevada on Feb. 7, 2024. Patrick T. Fallon | AFP | Getty Images CVS Health on Wednesday slashed its full-year profit outlook again and announced a new plan to cut $2 billion in expenses over several years…
-
Eli Lilly Zepbound, Mounjaro obtainable after shortages, FDA says
An injection pen of Zepbound, Eli Lilly’s weight loss drug, is displayed in New York City on Dec. 11, 2023. Brendan McDermid | Reuters All doses of Eli Lilly’s highly popular weight loss injection Zepbound and diabetes drug Mounjaro are now available in the U.S., according to an update on the U.S. Food and Drug…
